Vmbook Online ordering

Corium International Inc

Corium International, Inc. is a publicly-traded company listed on the NASDAQ stock exchange under the ticker symbol "CORI." The company is headquartered in San Francisco, California and is a biotechnology company focused on developing and commercializing novel healthcare products.

Here are some key pieces of information about Corium International, Inc.:

* Founded: 1995

* Headquarters: San Francisco, California

* Industry: Biotechnology

* Sector: Healthcare

* Ticker symbol: CORI

* Exchange: NASDAQ

* Market capitalization: Around $1.4 billion (as of March 2023)

* Products: Corium's lead product is Coruptine, a once-weekly, long-acting injectable dopamine agonist for the treatment of Parkinson's disease and dystonia. The company also has a pipeline of earlier-stage products in various therapeutic areas, including oncology, neurology, and endocrinology.

* Revenue: Corium reported $3.2 million in revenue for the third quarter of 2022, with the majority of its revenue coming from the sale of Coruptine.

* Net income: Corium reported a net loss of $14.7 million for the third quarter of 2022.

* Historical stock performance: Corium's stock price has been volatile over the past year, with a high of around $25 per share in February 2022 and a low of around $5 per share in October 2022. As of March 2023, the stock is trading around $12 per share.

* Key executives: Dr. William D. Rastetter, CEO; Dr. John P. McLaughlin, CSO; Jeffrey F. Miro, CFO; Dr. Timothy M. Mayer, COO.

Please note that this information is subject to change and may not be up to date. It is important to do your own research and due diligence before making any investment decisions.